

CV Paul Anantharajah Tambyah

Address: 1E Kent Ridge Rd, NUHS Tower Block, Singapore 119228

Email: mdcpat@nus.edu.sg

Phone: (65) 67724375

Current Appointments: Professor of Medicine, National University of Singapore, Senior Consultant ID Physician National University Hospital, Head, Infectious Diseases Research Coordinating Office, National Center for Infectious Diseases, Visiting Consultant, Singapore Armed Forces

Education: MBBS (Singapore) 1988, MD (Singapore) 2011, Dip American Board of Internal Medicine (Infectious Diseases) 1998,2008; Languages – English, Mandarin, Malay(spoken)

Selected Committees: President, Asia Pacific Society of Clinical Microbiology and Infection, Exco member, International Society for Infectious Diseases, Exco Member, Action for AIDS, Singapore, Chair, Institutional Review Board, National University of Singapore.

Selected Publications

1. Yan G, Lee CK, Lam LTM, Yan B, Chua YX, Lim AYN, Phang KF, Kew GS, Teng H, Ngai CH, Lin L, Foo RM, Pada S, Ng LC, **Tambyah PA**. Covert COVID-19 and false-positive dengue serology in Singapore. *Lancet Infect Dis.* 2020 Mar 4.
2. Bal C, Herbreteau CH, Buchy P, Rith S, Zaid M, Kristanto W, Han V, Reynaud C, Granjard P, Lépine B, Durand C, **Tambyah PA**. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')(2) fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study. *Lancet Infect Dis.* 2015 ;15:285-92
3. Lye DC, Archuleta S, Syed-Omar SF, Low JG, Oh HM, Wei Y, Fisher D, Ponnampalavanar SSL, Wijaya L, Lee LK, Ooi EE, Kamarulzaman A, Lum LC, **Tambyah PA**, Leo YS. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. *Lancet.* 2017;389(10079):1611-1618
4. Hsu LY, Apisarnthanarak A, Khan E, Suwantararat N, Ghafur A, **Tambyah PA**. Carbapenem-Resistant *Acinetobacter baumannii* and Enterobacteriaceae in South and Southeast Asia. *Clin Microbiol Rev.* 2017 ;30:1-22.
5. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. *BMJ.* 2013;346:f3039
6. Lee VJ, Yap J, Cook AR, Chen MI, Tay JK, Tan BH, Loh JP, Chew SW, Koh WH, Lin R, Cui L, Lee CW, Sung WK, Wong CW, Hibberd ML, Kang WL, Seet B, **Tambyah PA**. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. *N Engl J Med.* 2010;362:2166-74.
7. **Tambyah PA**, Koay ES, Poon ML, Lin RV, Ong BK; Transfusion-Transmitted Dengue Infection Study Group. Dengue hemorrhagic fever transmitted by blood transfusion. *N Engl J Med.* 2008;359:1526-7
8. Ehrlich HJ, Müller M, Oh HML, **Tambyah PA**, Joukhar C, Montomoli E, Fisher DA, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett N. A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture. *New Engl J Med* 2008;358:2573-2584
9. Harris PNA, **Tambyah PA**, Lye DC, Mo Y, et al Paterson DL. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With *E coli* or *Klebsiella pneumoniae* Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. *JAMA.* 2018;320:984-994.

Recent Academic Awards

2019	John A Forbes Fellow (Melbourne ID Group)
2019	Singapore Urology Association Lectureship
2014	YLLSOM Outstanding Researcher Award
2010	Rotating Professorship Award, Medical Alumni Association

Research Support (as Principal Investigator)

MOH CTGL13feb010– Ketotifen as a treatment for dengue fever - S\$1,200,000 (USD\$857,000)
NUH Clinician Researcher Grant NUHSRO/2014/121/CRG/07 - \$142,041.00 (USD \$103,000)
NMRC/H1N1R/004/2009 – Severe influenza ICU transmission study - S\$100,000 (USD\$71,400)
MOHCDPHRG12NOV25: Controlling antimicrobial use through reducing unnecessary treatment of catheter associated urinary tract infections - S\$740,000 (USD \$528,500)
SERC BEP 2010: POC_061 - Development of an Infection-resistant Urinary Catheter Coated by Short Antimicrobial Peptides - S\$450,000 (USD\$321,400)